BLUE News and Press, bluebird bio Inc. From 07/28/21

National Resilience and bluebird bio (BLUE) announce a strategic alliance aimed to accelerate the early research, development and delivery of cell therapies.BLUE shares up 2% premarket at $26.44.As part of the agreement, Resilience will acquire bluebird’s Research Triangle (b...

Resilience to acquire bluebird’s clinical and commercial suspension lentiviral vector manufacturing facility in North Carolina, retaining all current employees at the site Alliance designed to foster best in class cell therapy product and manufacturing innovation throug...

SKYSONA is the first and only gene therapy approved in the EU to treat early CALD CALD is a rare neurodegenerative disease that can lead to progressive, irreversible loss of neurologic function, and death One-time treatment with SKYSONA has been shown to have a durable...

The EMA's Pharmacovigilance Risk Assessment Committee confirms favorable benefit-risk balance of bluebird bio's (BLUE) Zynteglo for transfusion-dependent β-thalassemia patients.BLUE shares up 2% premarket at $30.97.The company has informed the EMA that it is li...

EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) confirms favorable benefit-risk balance of ZYNTEGLO Company has informed EMA of lift of voluntary temporary marketing suspension bluebird bio, Inc . (Nasdaq: BLUE) today announced that the Europe...

koto_feja/iStock via Getty Images John Leonard, president and CEO of Intellia Therapeutics (NTLA), said Thursday that the technology used for the breakthrough gene-editing results it announced earlier in the week can be "very, very successful" for other diseases. Speaking to CNBC, Leonard sai...

PhonlamaiPhoto/iStock via Getty Images Biotech companies that are focused on the gene editing space for treatments are continuing higher for the third straight day. Beam Therapeutics ([[BEAM]] +15.7%) and Editas Medicine ([[EDIT]] +16.6%) are up double-digit percentages. CRISPR Therapeutics (...

CRISPR can be utilized ubiquitously as a search and replace tool allowing scientists to identify DNA sequences. The potential uses of CRISPR are numerous across a large variety of fields including agriculture, chemical, pharmaceutical, and livestock industries. Emerging biotech co...

Cutting-edge pharma Legend Biotech (NASDAQ: LEGN) burst onto the scene at the 2017 American Society of Clinical Oncology (ASCO) meeting with fantastic early clinical trial results for its multiple myeloma treatment. Now, with even better data in hand after ASCO 2021, the company and...

ipopba/iStock via Getty Images Several gene editing stocks are flying high in afternoon trading, the beneficiaries of news from over the weekend on Intellia Therapeutics' (NTLA) gene editing candidate NTLA-2001. Besides Intellia, which is currently up 50% in afternoon trading, Beam ...